Centrillion Genomics TechnologiesCentrillion Genomics Technologies
Centrillion Genomics Technologies
Enabling Multidimensional Genomics
  • Home
  • About Us
    • Corporate Overview
    • Responsible Genomics
      • Genetic Information and Privacy
    • Management Team
      • Executive Team
      • Advisory Board
    • Careers
      • Working at Centrillion
      • Career Opportunities
    • Contact Us
  • Services
    • Genomic Services
    • Clinical Testing
    • Consumer Genomics
      • TribeCode DNA Ancestry Test
  • Technology
  • Support
    • Genomic Services FAQs
    • Clinical Testing FAQs
    • Consumer Genomics FAQs
    • Contact Us
  • Order Now
Menu back  

Centrillion expands executive team with new chief strategy officer

May 14, 2015

Palo Alto, California; May 11, 2015 – Centrillion Technologies, a leading genomic technology company developing and commercializing transformative genomic analysis tools, has named Dr. James Zhang as its new Chief Strategy Officer. Dr. Zhang, a geneticist turned entrepreneur and venture capitalist, will join the executive team with responsibilities in corporate strategy, strategic business development, investor relations, and Asia Pacific operations.

Genomics is a core technology empowering precision medicine and life sciences research.  The market for genomics tools is predicted to grow rapidly in the next decade with numerous applications in oncology, non-invasive prenatal testing, precision medicine, agricultural applications, and consumer genomics. Centrillion is developing and commercializing genomic technologies that dramatically improve accuracy, reduce costs, and improve efficiency of genomics research and diagnostics.

“We are excited to have Dr. Zhang join us,” noted Dr. Wei Zhou, President and CEO of Centrillion Technologies. “James’ experience in biotechnology, entrepreneurship, and corporate strategy and financing will greatly benefit our customers and collaborators.”

“Advances in genomics are outstripping the exponential curve of Moore’s Law by a big margin. I am extremely excited to join the Centrillion team to develop breakthrough technologies to enable the continuation of that trend,” added Dr. Zhang. “You don’t get the chance to build a billion dollar company every day.”

Before joining Centrillion, Dr. James Zhang was a founding partner at Formation 8, a Silicon Valley based venture capital fund with over $1B under management. He is also a senior advisor and Venture Partner of China based GRC SinoGreen Fund. Prior, James was a venture capitalist at Softbank China Venture Capital and Khosla Ventures. As a biotechnologist, James co-founded BioConsortia and Mendel Biotechnology, where he led business development. He received his undergraduate training in biological sciences from the University of Science and Technology of China. He has a PhD in Genetics from the University of California Davis and completed his post-doctoral and business training at Stanford University and the Stanford Graduate School of Business, respectively.

Executive Team
  • Wei Zhou, Ph.D., J.D.
  • Suzanne Dee, Ph.D.
  • Jeremy Edwards, Ph.D.
  • Michael Henry
  • Glenn McGall, Ph.D.
  • Janet Warrington, Ph.D.
  • James Zhang, Ph.D.
Latest News
  • Centrillion Taiwan Raises Financing from ARM IoT Fund
    July 31, 2018
  • Centrillion Technologies Announces WeDoctor Partnership
    July 31, 2018
  • Centrillion Technologies Adds Suzanne Dee as Vice President of Product Science
    March 17, 2016
  • Centrillion Adds Vice President of Technology Research and Operations in Taiwan
    March 17, 2016
  • Centrillion expands executive team with new chief strategy officer
    May 14, 2015
  • Centrillion Receives NIH Funding for Genomic Technology Development
    April 16, 2015
Region Selector
  • Centrillion US
  • Centrillion China
Centrillion Genomics Technologies
Copyright © 2016-2018 Centrillion Technology Holdings Ltd. All rights reserved.
  • Privacy Policy
bottom menu